Ebola Treatment Clinical Trials Face Hurdles As Number Of Patients Shrinks

ScienceInsider: ‘Positive’ results for Ebola drug upsets plans for trials
“…The Guinean government has already announced it wants to make [the experimental Ebola drug] favipiravir available to more people, and if the results hold up to greater scrutiny, they could force a change in the design of other clinical trials going forward. Meanwhile, the decline in new cases has investigators revamping or even canceling trials at a time when manufacturers finally have enough supplies to test some of the most promising experimental drugs…” (Kupferschmidt/Cohen, 2/10).

Washington Post: The search for an Ebola cure is gearing up — but there may be too few patients
“The race to find a cure for Ebola is heating up, with scientists launching experiments in West Africa that are among the most ambitious ever aimed at taming the devastating disease. But they are encountering an unexpected challenge: finding enough Ebola patients as the outbreak recedes…” (Brittain, 2/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.